Exponent vs Huron Consulting
EXPO and HURN side by side, both in management and public relations services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How EXPO and HURN compare
Exponent is the larger company, worth 1.5 times as much as Huron Consulting ($4.2B against $2.7B).
On earnings, Huron Consulting is cheaper: it trades at 25.5× trailing earnings, against 39.3× for Exponent.
Huron Consulting grew revenue faster over the last twelve months (13.6% versus 12.8% for Exponent).
Exponent keeps more of each dollar of sales as profit, with a net margin of 17.7% compared with 6.4% at Huron Consulting.
Exponent pays a dividend yielding 1.4%; Huron Consulting does not pay one.
Exponent scores higher on the StockData Score (20 against 14 for Huron Consulting), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | EXPO | HURN |
|---|---|---|
| Size and price | ||
| Market cap | $4.2B | $2.7B |
| Share price | $87.69 | $170.33 |
| Change, 1 year | 25.4% | 2.9% |
| Change, 5 years | −24.9% | 258% |
| Beta (5Y) | 0.24 | 0.65 |
| Employees | 1,313 | 305 |
| StockData Score | ||
| Total score | 20 (better) | 14 |
| Valuation score | 2 (better) | 1 |
| Growth score | 3 | 5 (better) |
| Performance score | 5 | 5 |
| Health score | 6 (better) | 3 |
| Dividend score | 4 (better) | 0 |
| Valuation | ||
| P/E | 39.3× | 25.5× (better) |
| P/S | 6.6× | 1.5× (better) |
| P/B | 14.4× | 7.0× (better) |
| EV/EBITDA | 29.8× | 15.6× (better) |
| P/FCF | 38.4× | 16.8× (better) |
| PEG | 21.41 | 1.50 (better) |
| FCF yield | 2.6% | 5.9% (better) |
| Fair value | $66.46 | $153.76 |
| Margin of safety | −31.9% | −10.8% (better) |
| Growth | ||
| Revenue growth (TTM) | 12.8% | 13.6% (better) |
| Revenue growth, 5Y average | 7.8% | 14.3% (better) |
| Net income growth (TTM) | 8.7% | 9.9% (better) |
| EPS growth (TTM) | 11.5% | 16.4% (better) |
| EPS growth, 5Y average | 6.0% | – |
| Profitability | ||
| Gross margin | – | 34.0% |
| Operating margin | 20.2% (better) | 10.3% |
| Net margin | 17.7% (better) | 6.4% |
| FCF margin | 17.2% (better) | 8.9% |
| Return on equity | 31.2% (better) | 26.9% |
| Return on invested capital | 43.8% (better) | 12.3% |
| Financial health | ||
| Debt / equity | 0.00 | 2.16 (better) |
| Net debt / EBITDA | – | 3.57 |
| Current ratio | 1.98 (better) | 1.71 |
| Altman Z-score | 10.26 (better) | 3.44 |
| Piotroski F-score | 5 | 6 (better) |
| Dividends and buybacks | ||
| Dividend yield | 1.4% | – |
| Payout ratio | 54.8% | – |
| Years of dividend growth | 13 | – |
| Dividend growth, 5Y average | 9.6% | – |
| Buyback yield | 5.1% | 8.8% (better) |
| Shareholder yield | 6.5% | 8.8% (better) |
| Ownership | ||
| Held by institutions | 97.8% | 99.3% |
| Held by insiders | 1.3% | 2.4% |
| Insider net buying, 12 months | −$2.7M (better) | −$6.4M |
| Short interest, % of float | 5.2% | 4.7% |
Go deeper
- EXPO stock overview
- EXPO income statement
- EXPO valuation and score
- HURN stock overview
- HURN income statement
- HURN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.